$ATYR
aTyr Pharma Inc

2020 Q1 Form 10-Q Financial Statement

#000156459020024729 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $8.065M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.590M $2.530M
YoY Change 2.37% -37.84%
% of Gross Profit
Research & Development $3.620M $3.350M
YoY Change 8.06% -45.53%
% of Gross Profit
Depreciation & Amortization $157.0K $167.0K
YoY Change -5.99% -9.24%
% of Gross Profit
Operating Expenses $6.206M $5.877M
YoY Change 5.6% -42.5%
Operating Profit -$5.877M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$110.0K -$260.0K
YoY Change -57.69% -41.83%
Pretax Income $1.750M -$6.140M
YoY Change -128.5% -42.46%
Income Tax
% Of Pretax Income
Net Earnings $1.752M -$6.137M
YoY Change -128.55% -42.47%
Net Earnings / Revenue 21.72%
Basic Earnings Per Share $0.25 -$2.54
Diluted Earnings Per Share $0.25 -$2.54
COMMON SHARES
Basic Shares Outstanding 6.882M 2.419M
Diluted Shares Outstanding 6.885M 2.419M

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.80M $43.00M
YoY Change 15.81% -41.97%
Cash & Equivalents $39.45M $13.00M
Short-Term Investments $10.40M $30.10M
Other Short-Term Assets $500.0K $1.100M
YoY Change -54.55% -42.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $50.40M $44.70M
YoY Change 12.75% -41.18%
LONG-TERM ASSETS
Property, Plant & Equipment $3.900M $5.000M
YoY Change -22.0% 110.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $200.0K
YoY Change -50.0% 122.22%
Total Long-Term Assets $4.000M $5.200M
YoY Change -23.08% 110.53%
TOTAL ASSETS
Total Short-Term Assets $50.40M $44.70M
Total Long-Term Assets $4.000M $5.200M
Total Assets $54.40M $49.90M
YoY Change 9.02% -36.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $800.0K
YoY Change -12.5% -45.28%
Accrued Expenses $2.700M $1.900M
YoY Change 42.11% -24.99%
Deferred Revenue $143.0K $630.0K
YoY Change -77.3%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $6.866M $7.800M
YoY Change -11.97% 11.0%
Total Short-Term Liabilities $10.45M $11.20M
YoY Change -6.74% 1.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $6.400M
YoY Change -100.0% -50.58%
Other Long-Term Liabilities $2.000M $2.800M
YoY Change -28.57%
Total Long-Term Liabilities $2.000M $9.200M
YoY Change -78.26% -28.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.45M $11.20M
Total Long-Term Liabilities $2.000M $9.200M
Total Liabilities $12.30M $20.40M
YoY Change -39.71% -14.9%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.10M $29.49M
YoY Change
Total Liabilities & Shareholders Equity $54.45M $49.90M
YoY Change 9.11% -36.43%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income $1.752M -$6.137M
YoY Change -128.55% -42.47%
Depreciation, Depletion And Amortization $157.0K $167.0K
YoY Change -5.99% -9.24%
Cash From Operating Activities $2.058M -$6.023M
YoY Change -134.17% -43.06%
INVESTING ACTIVITIES
Capital Expenditures $166.0K $10.00K
YoY Change 1560.0% -97.99%
Acquisitions
YoY Change
Other Investing Activities $11.57M -$3.350M
YoY Change -445.37% -128.13%
Cash From Investing Activities $11.41M -$3.355M
YoY Change -439.97% -129.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.78M -619.0K
YoY Change -2810.66% -7837.5%
NET CHANGE
Cash From Operating Activities 2.058M -6.023M
Cash From Investing Activities 11.41M -3.355M
Cash From Financing Activities 16.78M -619.0K
Net Change In Cash 30.24M -9.997M
YoY Change -402.52% -1283.08%
FREE CASH FLOW
Cash From Operating Activities $2.058M -$6.023M
Capital Expenditures $166.0K $10.00K
Free Cash Flow $1.892M -$6.033M
YoY Change -131.36% -45.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
143000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
208000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
755000
CY2020Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6866000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10445000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2035000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8065000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
24000
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-97000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-985000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6023000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
3081000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
14650000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11406000
CY2019Q1 life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
1381000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16779000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30243000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9210000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22962000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39453000
CY2020Q1 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
49800000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
343524000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-40000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322304000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
21186000
CY2020Q1 us-gaap Minority Interest
MinorityInterest
-161000
CY2019Q4 us-gaap Minority Interest
MinorityInterest
-160000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41967000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54447000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10714286
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9352498
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9352498
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
6206000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5877000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-6137000
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.54
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2418674
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.54
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2418674
CY2019Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6117000
CY2020Q1 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
423000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
33650000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
166000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
13995000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
10650000
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3355000
CY2020Q1 life Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
29485000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
157000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
423000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
571000
CY2020Q1 us-gaap Accretion Expense
AccretionExpense
129000
CY2019Q1 us-gaap Accretion Expense
AccretionExpense
201000
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000
CY2019Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-619000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9997000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
106000
CY2020Q1 life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
201000
CY2019Q1 life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
169000
CY2019Q1 life Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
630000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-236000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-578000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-65000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
630000
CY2020Q1 life Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2058000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to the clinical trials and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to us in our critical accounting estimates.</p>
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
38932
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.34
CY2019Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-14
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
502004
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1471671
CY2020Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
10
CY2020Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
4
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000
CY2020Q1 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Issuable in three separate tranches (the Term Loans), $10.0 million of which was funded in November 2016, $5.0 million of which was funded in June 2017 and $5.0 million of which was funded in December 2017.
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
754000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1031000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1062000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
404000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
436000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2815000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
714474
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
162434
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.51
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
111.43
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.38

Files In Submission

Name View Source Status
0001564590-20-024729-index-headers.html Edgar Link pending
0001564590-20-024729-index.html Edgar Link pending
0001564590-20-024729.txt Edgar Link pending
0001564590-20-024729-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20200331.htm Edgar Link pending
life-20200331.xml Edgar Link completed
life-20200331.xsd Edgar Link pending
life-20200331_cal.xml Edgar Link unprocessable
life-20200331_def.xml Edgar Link unprocessable
life-20200331_lab.xml Edgar Link unprocessable
life-20200331_pre.xml Edgar Link unprocessable
life-ex311_8.htm Edgar Link pending
life-ex312_9.htm Edgar Link pending
life-ex321_6.htm Edgar Link pending
life-ex322_7.htm Edgar Link pending
life-ex33_130.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending